Insulin taps hit the market value of hundreds of billions! "Gross margin one brother" changed owner.

Pharmaceutical Network July 13th, July 10, with the development of pediatric drugs characteristics of Huluwa officially listedthis year has 18 pharmaceutical companies landed a-share A shares, of which, insulin leader Gan Li Pharmaceuticals hit hundreds of billions of market value, a signed profit of 150,000 still not open board;in addition, Collum Pharmaceuticals, Changchun High-tech, Tianshili, Hualan Bio and other eight pharmaceutical companies have announced plans to spin off subsidiaries listeddata show that in July last year, the high-profile Co-tron board opened the market, detonated the A-share market2019 there are 18 pharmaceutical enterprises landing A-shares, of which 15 from the board, and this year with the new three-board system, GEM registration system reform and other heavyweight policies, pharmaceutical stocks are expected to reach a new highthis year 18 pharmaceutical enterprises landed A-shares, 60% of the "beach" branch of the board this year A-share-listed pharmaceutical companies insulin leader impact hundreds of billions of market value, Gan Li Pharmaceuticals a signed a wild profit of 150,000 still not open edifice June 29, Gan Li Pharmaceuticals officially landed on the Shanghai Stock Exchangeup to now, 10 consecutive one-word board, a big signed more than 150,000 yuan, market value of 86.2 billion yuan, if the harvest of two more up and down board, the market value will exceed 100 billiondata show that the company is mainly engaged in the reorganization of insulin analogue api and injection research and development, production and salesits main products include recombinant insulin glargine injection (commodity name: Changxiu), recombinant recombinant insulin injection (commodity name: quick show, refined protein zinc recombinant recombinant insulin-rejuvenate injection (25R)2019, the company's revenue of 2.895 billion yuan, net profit of 1.167 billion yuan, of which, insulin preparation revenue accounted for up to 95.10%, recombinant insulin injection is the company's main source of revenueaccording to, sales of insulin and its similar drugs in the terminal chemical drug of public medical institutions in China will be nearly 25 billion yuan in 2019from the competitive landscape of enterprises, Novo Nordisk, Sanofi and Lilly three foreign pharmaceutical companies have been in the top three positions, in 2019 the total market share of nearly 75%in recent years, the market share of Novo Nordisk, which was the leading company, has slowed as domestic pharmaceutical companies such as Ganli Pharmaceuticals, Tonghua Dongbao Pharmaceuticals and Federal Pharmaceuticals have continued to grow, and the market share has declined from 55.91 percent in 2015 to 47.41 percent in 2019, Gan Li Pharmaceuticals announced that its wholly-owned subsidiary Gan li Pharmaceuticals USA has obtained FDA approval for GLR 2007 to conduct Phase I clinical trialsthe drug is an innovative small molecule chemical developed by the company and is intended for use in a variety of late-stage solid tumor treatments, including gliomasGan Li Pharmaceuticals said that the new drug is expected to become a fully independent intellectual property rights, effective treatment of a variety of late-stage solid tumors, including glioma, a new type of targeted drug, with greater market potential and social benefits super 95%, "gross margin one brother" easy owner! Kanghua Bio-Pharmaceutical Unit "Maotai" June 16, Kanghua Bio officially landed on the GEM data show that the company is a comprehensive research, development, operating integrated vaccine production enterprises, at the same time for the first domestic market seller of diploblasts rabies vaccine production enterprises main business products include the freeze-dried human rabies vaccine (human diphmyloid cells) and the ACYW135 group meningococcal polysaccharide vaccine it is worth mentioning that The gross margin of Kanghua Bio in the first quarter of this year was as high as 95.95 percent, surpassing the number one in many years , Kanghua Bio disclosed a revised half-year lying forecast, expected to make a net profit of 180 million to 185 million yuan in the first half of 2020, up 112.33 percent to 118.23 percent year-on-year Kanghua Bio said, mainly the company's core product sican-dried human rabies vaccine (human diphmyelite cells) due to market demand and other factors, product sales increased as of the close on July 10, Kanghua Bio's share price reached 465.61 yuan after 17 consecutive one-word boards, surpassing Changchun Gaoxin (455.00 yuan) as the "most expensive" pharmaceutical stock 26 one-word boards! Wantai biological into the pharmaceutical stock TOP 20million Tai Biological on April 29 landed A shares, in the harvest of 26 upand after the opening board, has become this year's largest number of new pharmaceutical shares market capitalisation of 87.6 billion yuan, up more than 22 times, as of the close on July 10 it is worth mentioning that Wantai Bio with a bright performance into the pharmaceutical stocks TOP20, at present, the A-share market, Hengrui Pharmaceuticals, Meirui Medical, Pharmaceutical Mingkang and other 9 pharmaceutical stock market value of more than 100 billion scale data show that Wantai Bio's main business has in vitro diagnostic reagents, in vitro diagnostic instruments and vaccine research and development, production and sales, core products include HIV diagnostic reagents, viral hepatitis series diagnostic reagents recently, Wantai Bio announced that the use of funds raised to the wholly-owned subsidiary capital increase, the company intends to use the funds raised to the wholly-owned subsidiaries Ofwantai Bohai and Wantai Carey each increase dissonance of 150 million yuan each, Wantai Bohai is the fund-raising project "cervical cancer vaccine quality system improvement and internationalization project implementation of the main body, Wantai Carey is the fund-raising project "chemical luminous reagent manufacturing system automation technology transformation and internationalization certification project Wantai Bio said that the capital increase is in line with the company's development strategy, is conducive to enhancing the competitiveness of the enterprise's own market, promote the implementation of investment projects and business growth a huge loss of nearly 2 billion! Bai Otai hand holding "global drug king" landing board in February this year, Bai Otai successfully landed on the company board, as the second to the branch board launched an impact on the unprofitable enterprises, its every move has been the attention of the market 2016-2019, the cumulative net profit of Baiai lost nearly 2 billion yuan the reason for such a large-scale loss, mainly due to research and development investment and equity incentives industry analysts point out that regulators, in addition to the same concerns about unprofitable companies as other tech-makers, will pay particular attention to their future profitability and the disclosure of risk factors 's 2019 annual report shows that, in addition to the company's independent research and development of Adamu monoantithebiotic similar drug BAT1406 has been approved for listing, all of the company's products are in the research and development stage, has not yet carried out commercial production and sales, the company's products have not yet achieved sales revenue, the company has not yet made a profit and there is a cumulative loss as of December 31, 2019, Baiota has 1 product approved for market, there are 20 major products in research, of which 1 product has submitted ndA application, 3 products are in Phase III clinical research stage, 1 product is in Phase II clinical research stage, 4 products in Phase I clinical research stage Huluwa hot debut! Junshi creatures, three-born national health .. Listed in that A-share to be listed pharmaceutical enterprises into the second half of the year, in addition to Huluwa, Junshi Biological, Sansheng Guojian and other 5 pharmaceutical enterprises to be listed are from the company board Huluwa: July 10 officially landed on the A-share data show that Huluwa is based on the development of pediatric drugs, mainly engaged in traditional Chinese medicine and chemical research and development, production and sales product application sits in a number of drug applications, including respiratory, digestive, systemic and anti-infective the main products are pediatric pulmonary hot cough wheezing particles, injection of bromine broquine, compound plate blue root particles, gram cough tablets and other respiratory preparations; Junshi Bio: an innovative-driven biopharmaceutical company according to the prospectus, Junshi Bio has invested more than 1.7 billion yuan in research and development expenses in the past three years, with a compound annual growth rate of more than 85% its core product, Toripalimab, a mono-antiting injection (commodity name: Toi) was conditionally approved by NMPA in December 2018 and is the first domestically approved domestic PD-1 monoclonal antibody injection to be used to treat localized progression or metastatic melanoma following the failure of previous standard treatments sales of Trepri's mono-resist reaching 774 million yuan as of December 31, 2019 in addition to the first approved indications, the company is also conducting a number of clinical trials of Trepri monotopathy in addition, , the company is the first Chinese company to obtain NMPA IND approval for anti-PCSK9 monoclonal antibodies and anti-BLyS monoclonal antibodies, and has applied to the FDA in the United States and obtained the world's first clinical trial approval for anti-BTLA monoclonal antibody injections Said, with the continuous enrichment of product pipelines and further exploration of combination drug therapies, the company's innovation field will continue to expand to include small molecule drugs, antibody drug coupling (ADC) and more types of drug development, as well as cancer, autoimmune diseases, the next generation of innovative therapies exploration the drug stock is on fire! Colleen, Changchun High-tech, Tianshili ..." Zhahe" spin-off subsidiary listed this year A-share pharmaceutical enterprises proposed to spin off the subsidiary listing situation, The day before, Collum Pharmaceuticals disclosed the spin-off of its subsidiary Yili Chuanning Biotechnology Co., Ltd to gem listing plan Colum Pharmaceuticals said that after the spin-off, the company's equity structure would not change and it would still have a controlling stake in Kawaning Bio Although this spin-off will lead to the dilution of the company's holdings of Chuanning Bio, but through this spin-off, Chuanning Bio will further enhance operational efficiency, broaden financing channels, optimize product structure, improve the governance structure, is conducive to enhance the company's overall profit level in the future , including Collum Pharmaceuticals, in the first half of this year has Changchun High-tech, Tianshili and other eight A-share pharmaceutical enterprises announced plans to spin off subsidiaries listed as early as February, investors on the interactive platform to Liaoning Chengda to ask questions about the spin-off listing On February 28, , Dean Diagnostics announced that the company had decided to introduce investors to increase its capital and start the spin-off and listing process of its controlling subsidiary, Hangzhou Kailai spectrum Precision Medical Testing Technology Co., Ltd since then, Yan'an Bikang, Hualan Biology, Tianshili, Changchun High-tech and so on have issued plans in December last year, the CSRC officially issued "A number of provisions on the pilot listing of the subsidiaries of listed companies" to provide policy support for the spin-off of the subsidiaries of A-share companies to list on the domestic market in addition, this year's GEM registration system reform will usher in the first trial of the IPO, July 13, the Shenzhen Stock Exchange released the GEM Listing Committee held the first review meeting, pharmaceutical enterprises, Kantai Medical's initial application in it so far, the GEM reform and pilot registration system under the application for IPO a total of more than 250 enterprises industry analysts pointed out that with the new three-board system, GEM registration system reform and a series of policies, the pharmaceutical industry may usher in a new wave of capital at present, although the IPO speed up, but the scrutiny is tightening, which is also the regulator for the capital market strict control of the important performance Source: Oriental Wealth Network, Minnet Database, Listed Company Announcement Statistics as of July 10, the close of the market, if there is a mistake, please point .